“third-rock-ventures” Archives

in
Entry Author Date Location
On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO 07/06/20 San Francisco
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later 06/30/20 Boston
Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs 06/25/20 Boston
Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development 05/26/20 San Francisco
Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies 05/12/20 San Francisco
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021 05/11/20 San Francisco
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs 05/04/20 Boston
Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More 04/17/20 National
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer 02/12/20 San Francisco
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus 01/29/20 Boston
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers 01/17/20 San Francisco
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More 11/08/19 National
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More 09/13/19 National
The Winners of the 2019 Xconomy Awards Boston Are… 09/12/19 Boston
New BC Biotech Chinook Reels in $65M to Tackle Kidney Disease 08/22/19 National
Mark Levin Named Xconomy’s 2019 Lifetime Achievement Award Winner in Boston 07/31/19 National
After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs 07/09/19 San Francisco
With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field 06/19/19 San Francisco
Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More 06/07/19 National
To Catch Early Cancer, and Rivals, Thrive Banks on Hopkins Blood Test 05/30/19 Boston
Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More 05/10/19 National
Goldfinch Bio Lands $55M From Gilead in Kidney Drug R&D Pact 05/08/19 Boston
Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs 04/16/19 National
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
SPECIAL REPORT: 2019 Biopharma Outlook – Facing an Uncertain Future 03/01/19 National
MyoKardia Goes Solo as Sanofi Ends Precision Heart Drug Deal 01/02/19 San Francisco
Eyeing $500M, Moderna Outlines Plans for Biotech’s Biggest IPO Ever 11/09/18 Boston
Catch CRISPR 2.0, RNA-Targeting Drugs & More At “Disruptors” on Oct. 17 09/26/18 Boston
Agenda Posted for Boston’s Life Science Disruptors on Oct. 17 09/10/18 Boston
Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO 09/05/18 Boston
Page 1 of 17 next page »